NEW YORK (GenomeWeb News) – ILS announced on Friday it has acquired the Morrisville, N.C. site of Beckman Coulter Genomics and formed ILS Genomics.
ILS Genomics provides services in genotyping and gene expression, as well as biologics product safety testing. Sam Tetlow, chief business officer for ILS, was named general manager of ILS Genomics.
The company said that it has capabilities in key platforms for gene expression profiling, including Affymetrix, Illumina, Agilent, Sequenom, and Life Technologies business Applied Biosystems.
A spokesperson for Beckman Coulter, a Danaher business, told GenomeWeb Daily News that the purchase comprised of the building at the site and some assets, but not Beckman Coulter Genomics. She declined to disclose the terms of the deal. Tetlow added that ILS Genomics has about 20 employees currently.
Technology used by the company include microarrays and Sanger sequencing, he said.
ILS is based in Research Triangle Park, N.C., and provides research support to federal and commercial clients. Its core capabilities include investigative toxicology, genetic toxicology, molecular biology, histopathology, and environmental and information science services.